晨光生物(300138) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥1,817,862,277.48, representing a 14.71% increase compared to ¥1,584,746,474.76 in the same period last year[4] - Net profit attributable to shareholders was ¥135,043,557.83, up 26.30% from ¥106,924,931.52 year-on-year[4] - The company's basic earnings per share increased to ¥0.2535, a rise of 26.31% from ¥0.2007 in the same period last year[4] - The company reported a 30.62% increase in income tax expenses, reflecting the rise in profits during the reporting period[15] - Total operating revenue for Q1 2023 reached CNY 1,817,862,277.48, an increase of 14.74% compared to CNY 1,584,746,474.76 in the same period last year[36] - Net profit for Q1 2023 was CNY 139,942,815.94, representing a 30.93% increase from CNY 106,869,101.26 in Q1 2022[37] - Earnings per share (EPS) for Q1 2023 was CNY 0.2535, compared to CNY 0.2007 in the previous year, marking a 26.33% increase[38] Cash Flow and Assets - The net cash flow from operating activities was -¥135,845,984.90, a decrease of 379.81% compared to -¥28,312,350.64 in the previous year[4] - As of March 31, 2023, the company's cash and cash equivalents increased to ¥1,593,604,786.64 from ¥1,146,656,571.64 at the beginning of the year, representing an increase of approximately 39.1%[33] - The total current assets rose to ¥5,651,298,859.32, up from ¥4,926,772,712.74, indicating a growth of about 14.7%[33] - The company's inventory increased to ¥2,487,020,081.00 from ¥2,033,380,620.48, reflecting a rise of approximately 22.3%[33] - The total assets at the end of the reporting period were ¥7,637,338,957.57, an increase of 10.31% from ¥6,923,739,569.28 at the end of the previous year[5] - The total liabilities increased to CNY 4,274,955,745.12 from CNY 3,709,657,856.10, indicating a growth of 15.25% year-over-year[35] - The total equity attributable to shareholders of the parent company rose to CNY 3,310,166,549.84, up from CNY 3,164,817,273.47, reflecting a 4.59% increase[35] Investment and Income - Investment income increased by 628.60% year-on-year, attributed to increased financial management of idle funds[12] - The cash received from investment increased by 2,262,596.50% year-on-year, due to the recovery of principal from financial management and equity transfer payments[16] - The company reported an investment income of CNY 10,596,612.31, significantly higher than CNY 1,455,486.76 in the previous year, showcasing improved investment performance[37] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,004, with no preferred shareholders[21] - The largest shareholder, Lu Qingguo, holds 18.43% of the shares, amounting to 98,196,051 shares, with 73,647,038 shares pledged[21] - The total number of restricted shares at the beginning of the period was 104,548,148, with 3,553,125 shares released during the period, resulting in a total of 101,033,549 restricted shares at the end of the period[25] Research and Development - Ongoing R&D projects include improving the yield of chili red pigment and optimizing the production process of stevia[29] - The company is actively developing differentiated and customized products to enhance customer solutions and product value[28] - The company completed the development of several new products, including application-specific products and microencapsulated products, aimed at enhancing market competitiveness[30] - The company has made progress in the development of new health food products, including glucosamine calcium tablets, which are expected to enhance market competitiveness[30] - The company is focusing on improving the quality of its products, including the development of new extraction processes for chili peppers, to strengthen its competitive advantage[30] Operational Costs - Operating costs amounted to CNY 1,585,966,370.73, up from CNY 1,369,523,823.31, reflecting a year-over-year increase of 15.75%[37] - Cash paid for purchasing goods and services was 1,974,123,601.80 CNY, compared to 1,743,302,016.66 CNY in the same quarter last year[41] Financing Activities - The net cash flow from financing activities was 393,053,434.99 CNY, a recovery from -33,515,005.76 CNY in the same quarter last year[42] - The company received 754,687,439.90 CNY in cash from borrowings, up from 585,931,000.00 CNY year-over-year[42] - Cash paid for debt repayment was 167,759,305.56 CNY, a decrease from 543,989,960.00 CNY in the previous year[42]